Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:DCPHNASDAQ:PLRXNASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.56-1.4%$4.10$3.21▼$8.06$863.71M0.594.53 million shs3.48 million shsDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsPLRXPliant Therapeutics$1.28-2.3%$1.44$1.10▼$16.10$80.42M1.351.13 million shs1.20 million shsPTGXProtagonist Therapeutics$53.34-1.1%$47.94$30.67▼$60.60$3.34B2.25905,446 shs2.28 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%-2.96%-13.64%-29.63%-39.33%DCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PLRXPliant Therapeutics0.00%-10.88%-4.38%-15.48%-87.77%PTGXProtagonist Therapeutics0.00%-4.26%+15.68%+2.41%+65.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0718 of 5 stars3.51.00.04.42.72.50.6DCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APLRXPliant Therapeutics4.2567 of 5 stars3.04.00.04.73.01.70.6PTGXProtagonist Therapeutics1.4795 of 5 stars2.52.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89205.87% UpsideDCPHDeciphera Pharmaceuticals 0.00N/AN/AN/APLRXPliant Therapeutics 2.00Hold$13.31940.04% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1023.92% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, DCPH, PLRX, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/28/2025PTGXProtagonist TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M2.55N/AN/A$0.73 per share4.88DCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84PLRXPliant Therapeutics$1.58M49.73N/AN/A$5.00 per share0.26PTGXProtagonist Therapeutics$434.43M7.61$4.47 per share11.94$11.33 per share4.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.48N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)DCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/APLRXPliant Therapeutics-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7571.12N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)Latest PTGX, DCPH, PLRX, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81DCPHDeciphera PharmaceuticalsN/A4.193.94PLRXPliant TherapeuticsN/A11.0311.03PTGXProtagonist TherapeuticsN/A17.2517.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%DCPHDeciphera Pharmaceuticals70.96%PLRXPliant Therapeutics97.30%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%DCPHDeciphera Pharmaceuticals4.67%PLRXPliant Therapeutics8.00%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionOptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionablePTGX, DCPH, PLRX, and ARDX HeadlinesRecent News About These CompaniesProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20 at 6:40 PM | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20 at 1:39 PM | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19 at 3:53 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at CitigroupJune 19 at 1:27 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17 at 8:34 AM | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17 at 3:34 AM | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $65.44 Average Target Price from AnalystsJune 17 at 2:09 AM | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comGAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 13, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 SharesJune 11, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street ZenJune 8, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 7, 2025 | marketbeat.comShort Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%June 5, 2025 | marketbeat.com9 Analysts Assess Protagonist Therapeutics: What You Need To KnowJune 4, 2025 | benzinga.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC WainwrightJune 3, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial CorpJune 2, 2025 | marketbeat.comProtagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraJune 1, 2025 | businesswire.comWellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comNuveen Asset Management LLC Sells 80,877 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, DCPH, PLRX, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$3.56 -0.05 (-1.39%) Closing price 04:00 PM EasternExtended Trading$3.59 +0.03 (+0.87%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Deciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Pliant Therapeutics NASDAQ:PLRX$1.28 -0.03 (-2.29%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.02 (+1.56%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Protagonist Therapeutics NASDAQ:PTGX$53.34 -0.58 (-1.08%) Closing price 04:00 PM EasternExtended Trading$53.34 +0.00 (+0.01%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
